GeoVax's Multi-Antigen COVID-19 Vaccine Shows Strong Immune Response in Immunocompromised Patients
GeoVax Labs' GEO-CM04S1 vaccine demonstrates robust immunity in high-risk patients with blood cancers, potentially addressing a multi-billion dollar market where current vaccines have limited effectiveness.
GeoVax Labs, Inc. presented positive interim clinical results for its COVID-19 vaccine candidate GEO-CM04S1 at the European Society of Clinical Microbiology and Infectious Disease Conference, showing strong immune responses in immunocompromised patient populations. The data revealed no serious adverse events attributed to the vaccine and demonstrated potent, durable T-cell and cross-variant antibody responses that exceed those of standard-of-care vaccines.
In the chronic lymphocytic leukemia trial interim analysis, GEO-CM04S1 met its primary endpoint while the comparator mRNA vaccine did not, prompting continuation solely in the GEO-CM04S1 arm. The multi-antigen vaccine, based on a Modified Vaccinia Ankara vector, expresses both the Spike and Nucleocapsid proteins of SARS-CoV-2, designed to stimulate robust humoral and cellular immunity. Clinical studies demonstrate durable immune responses and cross-variant protection, including activity against Omicron subvariants such as XBB.1.5.
David Dodd, Chairman & CEO of GeoVax, stated that these results underscore the value and competitive advantage of their multi-antigen MVA vaccine platform. The company believes GEO-CM04S1 can address urgent unmet needs among immunocompromised patients, a market segment underserved by first-generation COVID-19 vaccines. COVID-19 continues to pose a significant threat to immunocompromised patients, representing a multi-billion-dollar global market where existing vaccines have limited value.
GeoVax is advancing its pipeline with an updated construct incorporating the Omicron KP.2 Spike gene slated for a 2026 trial, positioning the company at the forefront of next-generation COVID-19 vaccines. The vaccine is currently in three Phase 2 clinical trials evaluating its use as a primary vaccine for immunocompromised patients with blood cancers or post-transplant status, as a booster in patients with chronic lymphocytic leukemia, and as a booster in healthy adults previously vaccinated with mRNA vaccines. For more information about the company's clinical trials, visit https://www.geovax.com.